BioSpace News Archive

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences.

MaxCyte, Inc. announced Company management will participate in the following investor conferences:

BrainsWay Ltd. announced that it will report its third quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 16, 2022.

Providence Therapeutics Holdings Inc., a biopharmaceutical company developing messenger RNA vaccines and therapeutics, announces the appointment of Judyanna Yu, CPA, CA as chief financial officer.

LENSAR, Inc. today announced that the Company’s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022.

Bluestar Genomics, Inc. today announced the results of a validation study for its early pancreatic cancer detection test.

OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders.

Ocuphire Pharma, Inc. today announced that the positive results in night vision disturbances (NVD) patients from its earlier and first Phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol).

Sonnet BioTherapeutics Holdings, Inc. announced today that the safety of SON-1010 dosing in several cohorts has been formally reviewed in both Phase 1 clinical trials and that dose escalation is continuing as early data becomes available.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 46,500 shares of Astria’s common stock on November 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.